CelerisTx and Merck KGaA Forge AI-Powered Collaboration to Advance Targeted Protein Degradation Therapeutics

On February 9, 2022, CelerisTx announced a research collaboration agreement with Merck KGaA of Germany to discover and design novel small molecule binders and bifunctional protein degraders using CelerisTx's graph-based artificial intelligence (AI) technology platform.

Protein degradation-targeting chimeras (PROTACs) technology and molecular glues are becoming one of the hotspots in new drug development. CelerisTx, founded in 2020, is committed to filling the knowledge gap in the rational design of these compounds. The company's developed platform, Celeris One, is a closed-loop discovery engine capable of predicting biomolecular interactions. It can generate new chemical entities that meet the success criteria for relevant degraders and extend this knowledge to synthesis and biochemical validation. The application of this discovery engine is expected to streamline the discovery process of potent degraders while enhancing the productivity of upstream research and development.

References:

[1] CelerisTx in research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled degrader discovery. Retrieved February 9, 2022, from https://www.einnews.com/pr_news/562741852/celeristx-in-research-collaboration-with-merck-kgaa-darmstadt-germany-on-ai-enabled-degrader-discovery

[2] Menlo Park, CA, February 9, 2022 - CelerisTx in Artificial Intelligence research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled. Retrieved February 9, 2022, from https://www.biospace.com/article/menlo-park-ca-february-9-2022-celeristx-in-artificial-intelligence-research-collaboration-with-merck-kgaa-darmstadt-germany-on-ai-enabled-degrader-discovery/

[3] Merck KGaA enlists little AI player on protein degrader discovery. Retrieved February 9, 2022, from https://endpts.com/merck-kgaa-enlists-little-ai-player-on-protein-degrader-discovery/

(Original text has been abridged)

▽Follow 【WuXi AppTecGermany】WeChat Official Account